Beacon Biosignals turns nights into neural insights for earlier detection, faster drug trials and a new model of brain health at scale.
What if the most important health signals your body produces don’t happen at the doctor’s office, but while you’re asleep? What if, night after night, your brain has been quietly recording clues about your future health, long before symptoms show up, long before anything feels wrong?
We’ve built an entire healthcare system around a quick scan, a single test, a short visit. However, the brain doesn’t work in snapshots. It’s dynamic, constantly shifting, changing over time. The mismatch between how the brain behaves and how we measure it has held back progress in everything from mental health to neurodegenerative disease.
Boston-based neurotechnology company Beacon Biosignals is trying to close that gap, not with a bigger machine or a more complex hospital setup, but with a headband you wear to sleep.
Founded by neuroscientist Jake Donoghue and researcher Jarrett Revels, Beacon Biosignals is building an at-home system that records brain activity during sleep using EEG, or electroencephalogram, a method that tracks the brain’s electrical signals.
If that sounds clinical, it usually is. Traditionally, EEG requires a sleep lab, wires attached to your scalp and a night spent in an unfamiliar room under observation. It’s expensive, inconvenient and not exactly reflective of how people actually sleep.
Beacon flips that model. Their lightweight headband captures those same signals at home during normal sleep over multiple nights. The data is then processed using machine learning to identify patterns – how long you spend in deep sleep, how often your brain briefly “wakes up” and subtle shifts in sleep architecture that could signal something deeper [1].
“There’s a step-change in what becomes possible when you remove the sleep lab and bring clinical-grade EEG into the home,” Donoghue told MIT News. “It turns sleep from a constrained, facility-based test into a scalable source of high-quality data for diagnostics, drug development, and longitudinal brain health [2].” In other words, sleep becomes less of a black box and more of a continuous report card for the brain.
Here’s the part most people miss: the brain doesn’t power down when you sleep; it becomes more structured and more expressive. Donoghue describes neural activity during sleep as almost language-like, with patterns that can be read, tracked and compared over time. That makes sleep uniquely valuable: it’s repeatable, natural and it happens every night.
Beacon’s system leverages that consistency. Instead of relying on a single test, it builds a timeline, a longitudinal record of how the brain behaves across days, months, even years.
“We’re starting to take features of sleep activity and link them to outcomes in a way that’s never been done with this level of precision,” Donoghue said.
Precision matters most in diseases where time is everything. In conditions like Alzheimer’s and Parkinson’s, changes in the brain can begin years before symptoms appear. By the time memory loss or motor issues show up, significant damage may already be done. Beacon is working to catch those changes earlier, when intervention might still make a meaningful difference.
Beacon’s FDA-cleared device is already being used in more than 40 clinical trials globally, across conditions like depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Its primary customers aren’t consumers; they’re pharmaceutical companies. That’s a deliberate choice.
Drug development for brain disorders is notoriously slow and expensive, partly because researchers struggle to measure whether a treatment is working in real time. Many trials rely on behavioral assessments or cognitive tests that take months (or years) to show meaningful results.
Beacon offers something different: earlier signals. If changes in brain activity during sleep can indicate whether a drug is having an effect, companies can make faster decisions, whether to continue, adjust or stop a trial altogether. In an industry where timelines stretch long and failure rates are high, that kind of feedback is valuable.
This vision is backed by significant capital; as of April 2026, Beacon has secured $97 million in Series B funding – including a recent $11 million extension – from heavyweights like Samsung Next, Google Ventures and Innoviva, pushing their total cumulative funding past $132 million [3].
It would be easy to see Beacon as just another wearable company, but that perspective misses the bigger picture. The real asset isn’t the headband, but the data.
With every night of recorded sleep, Beacon is building what Donoghue describes as a “foundation model” of the brain, a large, growing dataset that captures how brain activity varies across individuals, conditions and time.
“It’s our belief that the dataset that’s going to transform brain health doesn’t exist yet – but we are rapidly creating it,” he said.
Think of it like a map, one that becomes more detailed the more people use it. That map could eventually help identify disease subtypes, match patients to the right treatments and even improve how clinical trials recruit participants. It shifts brain health from something reactive to something measurable, trackable and, crucially, predictable.
For longevity, Beacon’s approach lands on a fundamental truth: you can’t extend what you can’t see. Much of today’s longevity conversation focuses on metabolic health, fitness and nutrition. But brain health, despite being central to quality of life, still lags behind.
Beacon takes part in changing that, to bring the same level of continuous monitoring and early detection to the brain. There’s something radical about where this is happening: not in hospitals, but in bedrooms. Not in rare, one-off tests, but in everyday life.
Longevity is about preserving the systems that make those years meaningful. Memory. Cognition. Identity. If sleep can help us protect those things – if it can turn early whispers of disease into actionable insight – then it may be one of the most powerful and most underused tools we have. It’s been with us all along.
Photograph courtesy of Beacon Biosignals
[1] https://beacon.bio/products-services#dreem-3s
[2] https://news.mit.edu/2026/beacon-biosignals-maps-brain-during-sleep-0501
[3] https://beacon.bio/news/beacon-biosignals-upsizes-series-b-to-over-97-million
